DNA strand

Cervical Cancer: A New Era in Screening

At CC Diagnostics, we aim to improve the detection of cervical cancer. We are developing a PCR-based reagent kit that provides accurate and timely results, ensuring early intervention and better patient outcomes.

Learn MoreContact Us

Early Cancer Detection Through Epigenetics

Our cutting-edge technology allows for the early detection of cervical cancer, providing patients with a higher chance of successful treatment. With our innovative approach, we can identify abnormalities at the earliest stage, ensuring timely intervention and improved outcomes.

Why Early Detection Matters

Despite screening programs being widely available, cervical cancer goes largely undetected, leading to high morbidity and mortality. There is a global inequity in access to screening and treatment.

Cervical cancer cases go undetected
144,000
False positives lead to unnecessary treatment.
1.4 million
Most common cancer in women
4th

CC Diagnostics

Empowering women through optimal cervical cancer screening performance, availability and comfort.

At CC Diagnostics, we believe that early detection is key to improving patient outcomes. Our innovative medical advances are revolutionizing cervical cancer detection, providing accurate and timely results that can save lives.

Methica CC

Current Issues

Traditional screening typically involves a primary HPV test and, if positive, a subsequent Pap smear. For the Pap smear, the gynecologist takes a cervical scraping which is then analyzed by a technician under the microscope.

Almost 30% Missed Cancers

Pap smears are analyzed subjectively under the microscope, risking human error.

Painful & Uncomfortable

The cervical scraping collection is painful and creates both emotional and physical barriers, leading to only 15% global participation in screening programs

Long & Laborious Process

Pap smears require more manual processing and are not compatible with automation. Each 4-week delay in diagnosis results in a 10% increase in mortality.

Our Solution

Methica CC Kit

A PCR assay for cervical cancer screening using novel biomarkers.

* Product in development, not available for clinical use. Performance demonstrated in internal evaluations

Get in Touch
Cancers detected*
97%
More sensitive than Pap smear*
21%
Times less hands-on time
6X
Methica Kit

Everyone benefits

Molecular assays like the HPV test have already revolutionized screening once, introducing benefits like self-sampling for patients, automation for clinicians, and improved cost-effectiveness for payers. With fully molecular screening via HPV testing and Methica CC triage, everone would benefit.

Patients

Less waiting. More certainty. More comfort.

Clinics

Test up to 94 samples simultaneously. Improved patient management.

Healthcare systems

More cancers detected = less spending on treatments. Up to €700M saved.

Featured News

Clinical Study

Presenting our achievements on EUROGIN 2025 in Porto

👩‍🔬 Putting science into practice, strategic collaborations and learning from experts during our EUROGIN 2025 visit in Porto. Our Chief Scientific Officer Jolien de Waard shared the scientific highlights of our work during two great presentations. With 1600+ international participants from 78 different countries this is the platform to share our clinical validation data and let the world know about our Methica CC kit superior performance. The feedback is well received and we’re very excited about the follow-up and implementation projects. 

Accelerator

CC Diagnostics enters EIT Health Catapult Semifinals

🎉We’re thrilled to announce that CC Diagnostics was selected as one of 30 trailblazing European start-ups in the prestigious EIT Catapult! With this program's support, we’re more energized than ever to advance cervical cancer screening and make a global impact on women’s healthcare.

Clinical Study

CC Diagnostics Completes Methica CC Clinical Validation Study with Groundbreaking Results

CC Diagnostics has successfully completed a large clinical validation study using samples from the Dutch National Screening Program. The results? 97% sensitivity for cancer detection, outperforming the pap smear by 21%—all without compromising specificity. This study, conducted across multiple centers, reflects real-world performance and eliminates bias, marking a significant leap forward in cervical cancer diagnostics.